COPENHAGEN, Denmark, April 03, 2023 Ascendis Pharma A/S today announced that initial dose escalation data from the Company’s ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2. | April 3, 2023
– On track to fulfill all elements of Vision 3x3 to build a sustainable, profitable, leading biopharma company COPENHAGEN, Denmark, Jan. 08, 2023 Ascendis Pharma A/S today. | January 8, 2023